- Home
- TORO vs CNTB Comparison
TORO vs CNTB Comparison
Compare TORO & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TORO
- CNTB
- Stock Information
- Founded
- TORO 2022
- CNTB 2012
- Country
- TORO Cyprus
- CNTB United States
- Employees
- TORO N/A
- CNTB N/A
- Industry
- TORO Marine Transportation
- CNTB Biotechnology: Pharmaceutical Preparations
- Sector
- TORO Consumer Discretionary
- CNTB Health Care
- Exchange
- TORO Nasdaq
- CNTB Nasdaq
- Market Cap
- TORO 78.4M
- CNTB 90.3M
- IPO Year
- TORO N/A
- CNTB 2021
- Fundamental
- Price
- TORO $4.29
- CNTB $1.79
- Analyst Decision
- TORO
- CNTB Strong Buy
- Analyst Count
- TORO 0
- CNTB 2
- Target Price
- TORO N/A
- CNTB $7.50
- AVG Volume (30 Days)
- TORO 186.3K
- CNTB 90.8K
- Earning Date
- TORO 11-11-2025
- CNTB 11-13-2025
- Dividend Yield
- TORO N/A
- CNTB N/A
- EPS Growth
- TORO N/A
- CNTB N/A
- EPS
- TORO 0.01
- CNTB N/A
- Revenue
- TORO $20,143,992.00
- CNTB $1,965,000.00
- Revenue This Year
- TORO N/A
- CNTB N/A
- Revenue Next Year
- TORO N/A
- CNTB $453,067.90
- P/E Ratio
- TORO $332.10
- CNTB N/A
- Revenue Growth
- TORO 0.40
- CNTB N/A
- 52 Week Low
- TORO $1.70
- CNTB $1.23
- 52 Week High
- TORO $4.94
- CNTB $2.20
- Technical
- Relative Strength Index (RSI)
- TORO 85.02
- CNTB 55.28
- Support Level
- TORO $2.95
- CNTB $1.36
- Resistance Level
- TORO $4.45
- CNTB $1.58
- Average True Range (ATR)
- TORO 0.14
- CNTB 0.15
- MACD
- TORO 0.13
- CNTB 0.02
- Stochastic Oscillator
- TORO 88.91
- CNTB 81.73
About TORO Toro Corp.
Toro Corp acquires, owns, charters, and operates oceangoing tanker vessels and provides seaborne transportation services for crude oil and refined petroleum products. It operates in three reportable segments: the Aframax tanker, the LPG carrier segment, and the Handysize tanker. The company generates maximum revenue from the Aframax tanker segment.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.